Adjuvant TKI treatment of EGFR-mutant lung cancer-already ripe for decision?
作者信息
Kauffmann-Guerrero Diego
机构信息
Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany.
出版信息
Transl Lung Cancer Res. 2020 Aug;9(4):964-966. doi: 10.21037/tlcr.2020.04.13.
Abstract
摘要
相似文献
1
Adjuvant TKI treatment of EGFR-mutant lung cancer-already ripe for decision?辅助性酪氨酸激酶抑制剂治疗表皮生长因子受体突变型肺癌——是否已到决策时机？
Transl Lung Cancer Res. 2020 Aug;9(4):964-966. doi: 10.21037/tlcr.2020.04.13.
2
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
3
Mutation Profile of Resected -Mutated Lung Adenocarcinoma by Next-Generation Sequencing.下一代测序技术检测切除的 - 突变型肺腺癌的突变谱。
Oncologist. 2019 Oct;24(10):1368-1374. doi: 10.1634/theoncologist.2018-0567. Epub 2019 Mar 14.
4
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?I至IIIa期肺腺癌切除术后的回顾性研究：对于表皮生长因子受体（EGFR）突变患者，最佳辅助治疗方式是什么？
Clin Lung Cancer. 2015 Nov;16(6):e173-81. doi: 10.1016/j.cllc.2015.04.002. Epub 2015 Apr 20.
5
Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）敏感突变的晚期非小细胞肺癌（NSCLC）患者一线接受EGFR-TKI治疗时，就诊时体重减轻对生存的影响
J Cancer. 2018 Jan 1;9(3):528-534. doi: 10.7150/jca.22378. eCollection 2018.
6
[Effect of EGFR-TKI on lymphangiogenesis of lung cancer with EGFR mutation].[表皮生长因子受体酪氨酸激酶抑制剂对表皮生长因子受体突变型肺癌淋巴管生成的影响]
Zhongguo Fei Ai Za Zhi. 2014 Dec;17(12):834-8. doi: 10.3779/j.issn.1009-3419.2014.12.02.
7
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.酪氨酸激酶抑制剂初治表皮生长因子受体突变型非小细胞肺癌脑转移的管理：一项回顾性多机构分析。
J Clin Oncol. 2017 Apr 1;35(10):1070-1077. doi: 10.1200/JCO.2016.69.7144. Epub 2017 Jan 23.
8
Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.对于晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌患者，在疾病进展后继续使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）联合超选择性动脉灌注化疗。
Med Oncol. 2015 Dec;32(12):256. doi: 10.1007/s12032-015-0704-x. Epub 2015 Oct 23.
9
Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome.在 EGFR 突变型非小细胞肺癌患者中超越 EGFR TKI：仍有待克服的主要挑战。
Cancer Treat Rev. 2014 Jul;40(6):723-9. doi: 10.1016/j.ctrv.2014.03.006. Epub 2014 Apr 12.
10
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.T790M突变在EGFR突变的晚期肺腺癌患者EGFR-TKI再挑战治疗中的作用。
Oncotarget. 2017 Jan 17;8(3):4994-5002. doi: 10.18632/oncotarget.14007.
引用本文的文献
1
Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan.根治性非小细胞肺癌治疗方案方案管理直接医疗成本的比较成本分析：约旦的微观成本研究
Clinicoecon Outcomes Res. 2025 Jul 12;17:455-471. doi: 10.2147/CEOR.S520119. eCollection 2025.
2
Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis.表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者辅助靶向治疗与化疗的综合比较：一项成本效益分析
Front Oncol. 2021 Mar 25;11:619376. doi: 10.3389/fonc.2021.619376. eCollection 2021.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).转化医学学会关于表皮生长因子受体（EGFR）突变型肺癌术后管理的共识（2019年版）
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
3
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
4
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
5
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
6
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.厄洛替尼辅助治疗与安慰剂对照用于 IB 期-IIIA 期非小细胞肺癌患者（RADIANT）：一项随机、双盲、III 期临床试验。
J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
7
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.吉非替尼对比安慰剂用于完全切除的非小细胞肺癌：NCIC CTG BR19 研究结果。
J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.
8
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
9
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.表皮生长因子受体突变型切除肺癌的不同临床病程：1118 例手术标本检测结果及辅助吉非替尼和厄洛替尼的影响。
J Thorac Oncol. 2012 Dec;7(12):1815-1822. doi: 10.1097/JTO.0b013e31826bb7b2.
10
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
Zotero 插件